Prostate Cancer Care: Overcoming Challenges in Delivering Germline Testing to Veterans

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neeraj Agarwal, MD, FASCO

TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomized to receive either enzalutamide plus talazoparib or enzalutamide plus placebo, and the researchers found that there was a 37 percent reduction in risk of progression or death among those who received enzalutamide plus talazoparib. Dive further into the findings and their implications for patients with mCRPC with Dr. Charles Turck and Dr. Neeraj Agarwal, Professor of Medicine at the Huntsman Cancer Institute at the University of Utah.

Host: Rishi Sekar, MD

A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, counties in the United States that had the highest prostate cancer mortality were less likely to have any clinical trials in the area. Dive further into the results with Dr. Rishi Sekar, who presented the “Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations” session at the 2024 ASCO Genitourinary Cancers Symposium.

Host: Zachery Reichert MD, PhD

If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who had pain when entering the study, 45 percent had their pain improved with chemotherapy. Dive more into the findings with Dr. Zachery Reichert, who presented the “Sequencing Hormonal Therapies After Treatment Intensification” session at the 2024 ASCO Genitourinary Cancers Symposium.

Guest: Caron A. Jacobson, MD

CD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR T-cell therapies have historically been given in the inpatient setting, interest in outpatient delivery is growing, and this option may become more feasible if logistical issues and lack of multidisciplinary collaboration between the community provider and the CAR-T cell therapy center can be overcome.

AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies.

Guest: Jessica E. Hawley M.D. M.S.

For patients who start out with hormone sensitive prostate cancer, there's a period of time where the prostate cancer cells are responsive to suppressing testosterone production. So there’s a nice disease response early in that time period after diagnosis and when initial treatment has begun, but how long is each patient going to respond to that initial treatment, and what role does the multidisciplinary team have? Dive in with Dr. Jessica Hawley, Medical Oncologist at Fred Hutch Cancer Center and an Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine.

Guest: Jessica E. Hawley M.D. M.S.

The National Comprehensive Cancer Network (NCCN) has recommended new guidelines for the treatment of prostate Cancer. In this episode, you’ll learn about the top three biggest changes to the NCCN guidelines. Tune in with Dr. Jessica Hawley, Assistant Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine, who will also present this topic at the ASCO GU Symposium 2024.

Host: Daniel Kwon, MD

Between patient anxiety and insurance implications, there are several challenges associated with delivering germline testing to veterans with advanced prostate cancer. Learn more about these challenges and proposed solutions with Dr. Daniel Kwon, who presented the “Challenges in Patient-Centered Germline Testing Delivery for Veterans with Advanced Prostate Cancer” session at the 2024 ASCO Genitourinary Cancers Symposium.

Host: Neal Shore, MD

Between 20 and 50 percent of patients with high-risk localized prostate cancer will develop biochemical resistance, but historically, no Level I evidence for treatment was available. That’s why the EMBARK study is the first phase 3 trial to develop Level I evidence looking at monotherapy T suppression versus monotherapy enzalutamide versus combination enzalutamide and leuprolide. Dive into the findings with Dr. Neal Shore, who presented the “Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study” session at the 2024 ASCO Genitourinary Cancers Symposium.

Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Frank dela Rama, RN, MS, AOCNS, AGN-BC

Learn about the APP’s evolving role in caring for patients receiving PARP inhibitors for prostate cancer in this on-demand webcast capturing a live presentation by Clinical Nurse Specialist Frank dela Rama, RN, MS, AOCNS, AGN-BC.

Guest: Neeraj Agarwal, MD, FASCO
Guest: Elena Castro, MD, PhD
Guest: Neal Shore, MD, FACS
Guest: Axel S. Merseburger, MD

While the development of advanced prostate cancers is largely influenced by androgen receptor (AR) signaling, DNA-damage response (DDR) pathways also contribute to disease progression. AR axis-targeted therapies (ARATs) have been the standard of care for first-line mCRPC. Inhibiting PARP activity is an effective strategy for targeting malignant cells with limited DNA repair capacity due to DDR gene mutations, leading to synthetic lethality. There may be a synergy between ARATs and PARP inhibitors (PARPi), as ARATs can induce HRR deficiencies and PARP inhibitors can increase the activity of ARATs through AR-dependent transcription. Recent clinical trial results have demonstrated that the combination of PARPi with ARATs is safe and effective for the first-line treatment of patients with mCRPC, with 3 combinations now FDA-approved: olaparib + abiraterone, talazoparib + enzalutamide, and niraparib + abiraterone.

This activity will provide expert contextualization of evidence from first-line mCRPC clinical trials exploring these combinations, including insights about the differentiation of both treatment and patient selection, as well as management of treatment-related toxicities. Given the differences in approvals and guidelines between the US and European context, this Ryder Cup themed Expert Panel Discussion will compare and contrast the approach in both regions, giving participants comprehensive education on …